Analytical Development Services
Product Description
WuXi STA
-
Country/Region:United States
-
On CPHI since:2015
-
Certificates:3
-
Employees:5000+
Categories
WuXi STA
-
Country/Region:United States
-
On CPHI since:2015
-
Certificates:3
-
Employees:5000+
More Products from WuXi STA (15)
-
Product Parenteral Production Services
Our formulation development & analytical teams have rich experience in injectable drug development from preclinical studies through clinical trials to commercial launch, with 85,000+ characterization tests yearly.
We support a variety of dosage forms and filling formats for injectable drugs ... -
Product Small Molecule API Development & Manufacturing
WuXI's unrivaled API development platform provides our client with a robust platform to bring their drug to market. With a proven track record of success and trust in bringing life changing therapeutics to market, we are a go-to partner for clients looking for tailored and customized drug development and m... -
Product Bioavailability Enhancement & Advanced Delivery Technologies
Our bioavailability toolbox offers a customizable solution to your drug delivery challenges.
- Spray-Dried Dispersion (SDD)
- Hot Melt Extrusion (HME)
- Nano-suspensions & Lipid Nanoparticles
- Softgel & Liquid Filled Capsules
- Injectable Formulations\
-
Product Peptide CRDMO Platform
WuXi TIDES's Peptide platform includes a complete offering of services to bring your protein therapeutic to market faster while supporting a wide variety of conjugates including PPMO, Peptide-Antibody, Peptide-Linkers.
Services include but are not limited to: - Comprehensive Discovery Service... -
Product Oligonucleotide CRDMO Platform
WuXi TIDES has a robust and integrated Oligo API Platform, offering R&D and manufacturing services from preclinical to commercial scale and operating out of our US FDA inspected facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modalities inc... -
Product Highly Potent API (HPAPI), ADC Payload, and Payload-Linker Manufacturing
Our Jinshan and Changzhou sites are equipped with multiple R&D labs as well as a dedicated cGMP HP Kilo lab and plant for producing and manufacturing highly potent APIs (HPAPI's), antibody drug conjugates (ADC's), payloads, and payload-linkers. We currently offer drug product manufacturing at STA’... -
Product in-vivo PK Studies
Our drug product pre-formulation and formulation development services can also includes in vivo PK studies, conducted with multiple animal species and a rapid turnaround time. This additional service further extends our full suite offering to our clients while eliminating the need for additional vendor sou... -
Product Injectable Formulation Development & Fill-Finish Services
WuXi STA offers a wide range of tailored services and solutions for clients developing injectable formulations. Form types include solution, emulsion, sterile powder (lyophilized) and liposome. Our offering includes formulation development, performance analysis and characterization testing, and fill/... -
Product Global Regulatory Affairs & CMC Submission Support
WuXi STA's dedicated Global Regulatory Affairs CMC teams offers comprehensive CMC documentation support for IND, CTA, MAA, and NDA applications in western countries and China. Our highly experienced team works with your NCE programs to prepare Module 2 and Module 3 of your regulatory dossier through foreca... -
Product Packaging & Labeling Solutions
At WuXi STA, we understand the need for flexibility at the early stages of clinical testing and how aspects such as effective dose, stability and compliance requirements can change your needs abruptly. Our packaging team will work with you to collect the relevant data and test various packaging options as ... -
Product Oral Dose Drug Product Development & Manufacturing
WuXI STA's comprehensive drug product development platform for oral dosage forms offers our clients a complete line of solutions from pre-formulation development through to final product manufacture at commercial scale. Our capabilities include;
• Solid oral tablet/capsule (including liquid... -
Product Clinical Supply Services
WuXi STA's Clinical Supply Services provide you with full life cycle management from global comparator sourcing, labelling and packaging, storage and distribution, as well as return and destruction. Our industry-leading CMC project management is carried out in an integrated “teamwork” mode, which ensures a...
WuXi STA resources (9)
-
News New drug product service delivers expedited CTM
Biotech and pharma innovators are facing considerable challenges to find CDMO partners with capacity and capability to quickly develop and deliver high-quality CTM with flexible options+
-
Sponsored Content End game strategies to reach patients globally and swiftly
The journey for new therapies is long; wondering if a proven therapy will be produced and distributed efficiently to reach the intended markets as soon as possible should not be another burden
-
Video Case Study - Integrated CMC to IND in 10 Months
A Case Study of WuXi Speed and Service for a client. The project, which encompassed an integrated CMC approach to bring a molecule to IND phase was completed in 10 months -
News Hoth Therapeutics and WuXi strike API and drug product deal for cancer therapeutic
WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide -
Video WuXi STA IND Enabling Preformulation Package
WuXi STA's IND Enabling Preformulation Package (IEPP) is an integrated developability assessment service for new chemical entities (NCEs) to efficiently identify challenges and solutions earlier for higher success rates and lower overall costs. This video explains the package and process. -
News WuXi STA completes acquisition of its first European facility
The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms
-
Brochure F2CS: Fast to Clinical Supply
F2CS - fast to clinical supply service package delivers reliable clinical trial materials (CTM) fast with flexible options custom developed by highly experienced integrated teams equipped with advanced technologies, working in parallel to save time. -
Whitepaper IND Enabling Pre-formulation Package (IEPP)
WuXi STA's pre-formulation package IEPP (IND Enabling Pre-formulation Package) helps you select the best drug candidates at late discovery phase and develop the most suitable formulation for phase I in 8-12 weeks,










